Key result
SR-17018 emerges as a recreational preclinical mu-opioid agonist lacking established human safety or efficacy data.
Why the study?
The emergence of research grade compounds like SR-17018 as recreational substances creates clinical uncertainty due to lack of human data for overdose management.
Highlights the clinical risks and uncertainty introduced by the internet sale of unapproved 'research grade compounds' like the opioid SR-17018 for recreational use.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“DEA points to online forums that report SR-17018 can reduce or reset opioid tolerance. They argue that a person who later returns to opioid use may therefore face an increased overdose risk because that tolerance is gone. Losing opioid tolerance is what happens when someone stops taking opioids. Are we really going to call getting people off opioids an imminent threat to public safety?”
Clinicians should screen for unapproved research opioids like SR-17018; review leaves open prevalence, safety, and regulatory needs.
Several internet sites promote the sale of "research grade compounds."Although the purchaser attests that they are over 18 years of age, they know that the substances have not been approved by regulatory agencies and promise that they will not use them for human consumption, the compounds are supplied in tablet form, which is inconvenient for research use but very convenient for human consumption.One such compound is the opioid SR-17018 (aka "SR-17").SR-17018 was originally synthesized at Scripps Research as part of a discovery effort to test whether a G-protein-'biased' mu-opioid receptor (MOR) agonist could separate the undesirable opioid effect of respiratory depression from the desirable effect of analgesia.It never progressed through the stages necessary for human clinical trials, so it remained a research "tool" drug.Regardless of the initial intent, the United States Drug Enforcement Agency (DEA) alerts that some "research grade compounds" such as SR-17018 are emerging as recreational or abused substances.If so, the absence of adequate human data creates a problem for healthcare providers who may encounter an overdose of such a compound without an adequate evidence base upon which to draw.This narrative review presents SR-17018 as a case study of the clinical uncertainty that a "research grade compound" introduces.It synthesizes in vitro, ex vivo, and plausible human pharmacology of SR-17018, and it presents an emergency department physician's experience with a suspected SR-17 overdose.
No takes yet. Share an insight, caveat, or question.
Raffa et al. (2026) conducted a review in Opioid overdose and substance use disorder. SR-17018 was evaluated. SR-17018 is a preclinical mu-opioid receptor agonist with atypical receptor engagement that has emerged as a recreational substance without established human safety or efficacy data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: